Cost-saving innovations may improve overall outcomes, even when they are slightly less effective than available options, by permitting more efficient reallocation of resources. We used the Tufts Cost-Effectiveness Analysis (CEA) Registry and Medicare National Coverage Determinations (NCD) Database to identify medical innovations that might offer favorable "decisively cost-effective" tradeoffs defined as $10,000 or less per QALY and $50,000 or less per life year saved. RESULTS: Personalized medicine: Factors influencing reimbursement The strength of evidence for existing personalized medicine (PM) technology varies widely and, along with endorsement of clinical guidelines, appears to be the strongest predictor of reimbursement. To date, the value and hope of PM has outstripped the available evidence. Stay tuned for upcoming updates.

Cost-Effectiveness Analysis (CEA) Registry Updates CEA is the home of the CEA Registry (www.cearegistry.org). We have now updated the CEA Registry through the first half of 2009. The full 2009 data will be posted soon.

Welcome New CME Staff
Melvyn Lin, PhD, is an Assistant Professor and is currently involved in a number of projects including analyses of health care costs of Alzheimer’s disease, factors associated with adoption of cost-effectiveness research for cancer treatments and diagnostics, and promotional claims by pharmaceutical companies. James Chambers, M.Pharm., M.Sc., is a Project Director and leads and works on projects including the National Survey of U.S. Oncologists, research using our database of Medicare national coverage determinations shows evidence that providers are waiving co-pays to provide care, and does less. Early evidence on the quality of care provided by Special Needs Plans. Making Cost-Effectiveness Analysis Relevant: Cost-Effectiveness Analysis in the Southwest Quadrant: Adopting medical technology that costs less and does less. Does adjusting for health-related quality of life matter in cost-effectiveness analyses? A comparison of cost-effectiveness analyses that do and do not adjust for health-related quality of life. Medicare and the Medical Technology Assessment Process: What’s it all about? Medicare and medical literature, review of the occupational healthcare system. He also serves as a reviewer for the CEA Registry.

Upcoming Presentations

May 20, 2010

- Medicare, health reform and the future of effectiveness requirements.
- Medicare and Medicaid: How it’s going to work.

May 21, 2010

- Cost-Effectiveness Analysis in the Southwest Quadrant: Adopting medical technology that costs less and does less.
- Does adjusting for health-related quality of life matter in cost-effectiveness analyses? A comparison of cost-effectiveness analyses that do and do not adjust for health-related quality of life.

June 4, 2010

- Making Cost-Effectiveness Analysis Relevant: Cost-Effectiveness Analysis in the Southwest Quadrant: Adopting medical technology that costs less and does less.
- Does adjusting for health-related quality of life matter in cost-effectiveness analyses? A comparison of cost-effectiveness analyses that do and do not adjust for health-related quality of life.

June 11, 2010

- Medicare and the Medical Technology Assessment Process: What’s it all about?
- Medicare and medical literature, review of the occupational healthcare system.

Upcoming Course: May 24-25, 2010

American Society of Health-System Pharmacists
- Cost-Effectiveness Analysis in the Southwest Quadrant: Adopting medical technology that costs less and does less.
- Does adjusting for health-related quality of life matter in cost-effectiveness analyses? A comparison of cost-effectiveness analyses that do and do not adjust for health-related quality of life.

Announcing the 2010-2011 Sponsorship Program

The Center for the Evaluation of Value and Risk in Health (CEVR) is accepting applications for its 2010-2011 Sponsorship Program. Our sponsorship program helps to maintain and improve our Cost-Effectiveness Analysis (CEA) Registry and Medicare National Coverage Determinations (NCD) Database. Six new corporate sponsors received complete access to the CEA Value Databases, an invitation to meet other sponsors and organizations, and an opportunity to provide valuable feedback about how to become a sponsor. Please contact our Research Director, Dr. Peter Neumann.